Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

705
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
705
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

1.4K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.4K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

367
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
367
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

1.2K
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
1.2K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

954
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
954
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

388
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
388

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Detergent-Containing Toothpaste Decreases Esophageal Mucosal Impedance and Alters Salivary Properties in Humans.

Allergy·2026
Same author

Connecting the Dots Between Theory and Practice: Speaking With Your Patients About IBS-C Management.

Gastroenterology & hepatology·2026
Same author

Managing the Diagnostic and Therapeutic Challenges of Irritable Bowel Syndrome.

Gastroenterology & hepatology·2026
Same author

Rapid Gastric Emptying: Insights from a Large Cohort Study on a Controversial Disorder.

Digestive diseases and sciences·2026
Same author

Correction to: Abdominal Symptom Improvement During Clinical Trials of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation: A Post Hoc Analysis.

The American journal of gastroenterology·2026
Same author

Design of Treatment Trials for Disorders of Gut-Brain Interaction.

Gastroenterology·2026

Related Experiment Video

Updated: Apr 18, 2026

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

7.2K

Medication risk-taking behavior in functional dyspepsia patients.

Brian E Lacy1, Jerry Yu1, Michael D Crowell2

  • 1Division of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Section of Gastroenterology and Hepatology, Lebanon, New Hampshire, USA.

Clinical and Translational Gastroenterology
|January 9, 2015
PubMed
Summary

Patients with functional dyspepsia (FD) are willing to accept significant risks, including a 12.7% chance of sudden death, for a chance to cure their symptoms. Understanding patient risk tolerance is crucial for developing effective FD treatments.

More Related Videos

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes
06:01

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes

Published on: July 26, 2024

1.2K

Related Experiment Videos

Last Updated: Apr 18, 2026

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

7.2K
Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes
06:01

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes

Published on: July 26, 2024

1.2K

Area of Science:

  • Gastroenterology
  • Clinical Psychology
  • Health Economics

Background:

  • Functional dyspepsia (FD) lacks approved treatments, leaving patients with unmet medical needs.
  • Understanding patient risk tolerance is essential for developing new FD therapies.

Purpose of the Study:

  • To assess the willingness of FD patients to accept risks for a potential cure.
  • To explore the relationship between FD symptom severity and risk-taking behavior.

Main Methods:

  • A questionnaire was administered to FD patients (Rome III criteria).
  • Standard gamble (SG) method assessed risk tolerance for a hypothetical FD cure.
  • Validated scales measured FD severity, quality of life, and psychological factors.

Main Results:

  • Nearly half of FD patients would accept a 12.7% risk of sudden death for a 99% chance of cure.
  • Most patients experienced moderate to mild FD symptoms, with long-standing conditions.
  • Many patients reported adverse side effects from previous FD medications.

Conclusions:

  • FD patients demonstrate a high willingness to accept substantial risks for symptom relief.
  • Physicians must understand patient risk aversion to facilitate informed treatment decisions.
  • Further research is needed to develop safer and more effective FD treatments.